Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome - Nelson, Maria T; Wolter, Daniel J; Eng, Alexander; Weiss, Eli J; Vo, Anh T; Brittnacher, Mitchell J; Hayden, Hillary S; Ravishankar, Sumedha; Bautista, Gilbert; Ratjen, Anina; Blackledge, Marcella; McNamara, Sharon; et al. (Thorax, 2020)
Keywords: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibiotics; Bacteria; Bacteria - genetics; Bacteria - isolation & purification; bacterial infection; Bacterial Infections - prevention & control; Child; Clinical outcomes; Cystic fibrosis; Cystic Fibrosis - microbiology; Cystic Fibrosis - physiopathology; Forced Expiratory Volume; Genes; Humans; Maintenance Chemotherapy; Metagenome - drug effects; Microbiota; Microbiota - drug effects; Middle Aged; Pathogens; Respiratory infection; Severity of Illness Index; Spirometry; Sputum - microbiology; Staphylococcus infections; Studies; Taxonomy; Time Factors; Tobramycin - pharmacology; Tobramycin - therapeutic use; Young Adult; bacterial infection; cystic fibrosis; respiratory infection